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molecular pathogenesisNeuromuscular diseases encompass cellular disorders of the
motor-unit, which include the lower-motor neurons in the spinal-cord,
peripheral-nerve Schwann cells, neuromuscular junctions, and skeletal
muscle ﬁbers.
Neuromuscular disorders can be primary, or consequent to another
illness, such as cancer, collagen-vascular disorder, or a generalized
autoimmune, metabolic, deﬁciency infectious or toxicity disorder, and
they are disabling millions of persons. Moreover, muscle weakness
and frailty with ageing are virtually inevitable, generally beginning to
become manifest beyond the age of 40 — they progress to various
degrees, and are unstoppable. They can lead to reduced mobility,
increased risk of falling, injury, paralysis, and even death.
In neuromuscular diseases, themotor component involvement causes
muscle weakness and atrophy, resulting in falling and various degrees
of paralysis, including involvement of limbs, breathing, swallowing,
and, infrequently, eye movements. All are troublesome, frustrating
and crippling, and some are dangerous and/or rapidly fatal. Motor
involvement also can cause painfulmuscle cramps and spasms. Involve-
ment of the sensory component of the neuromuscular system causes
pain, numbness, tingling, incoordination of limbs, imbalance and falling.
For neuromuscular diseases there is an abundant efﬂorescence of
new information very-cogent to: a) diagnosis and understanding of
pathogenesis (e.g. genetic mutations, characteristic muscle biopsy
abnormalities, and various speciﬁc biomarkers); and b) newly-
discovered steps of pathogenic pathways leading to formulation of
current and future treatments (e.g., disease-speciﬁc targeted therapy).
Recent clariﬁcation of genetic abnormalities involved in several
hereditary neuromuscular diseases has greatly added to our under-
standing of molecular mechanisms involved in them, as well as in
several relevant sporadic neuromuscular diseases.
The newest, fascinating details of examples in each category are
presented by experts.http://dx.doi.org/10.1016/j.bbadis.2015.01.002
0925-4439/© 2015 Elsevier B.V. All rights reserved.Valerie Askanas MD, PhD is a neurologist who earned her
MD, and later PhD in immuno-neurobiology from the
Warsaw Medical University. She immigrated to New York
in 1969 and joined the Cornell-afﬁliated Institute for Muscle
Disease, where she established a muscle tissue-culture lab
and developed a method for culturing an abundant amount
of spontaneously-twitching embryonic chick- and rat skele-
tal muscle, which served as models to study their basic bio-
logic properties, including applications to this system of her
own biochemical, immunologic and electron-microscopic
techniques. Subsequently, shewas at theNewYorkUniversi-
ty Medical School where she began to develop her unique
method for culturing adult human muscle-ﬁbers from satel-
lite cells of small portions of diagnostic patient biopsies, to
which she applied various ultrastructural, immunologic and biochemical techniques.
In 1977 shemoved to theNIH to join Dr. King Engel where she established her own tissue-
culture lab and continued her innovative research on human cultured muscle ﬁbers as a
model to study pathogeneses of human neuromuscular diseases.
In 1981, Drs. Askanas and Engel moved to the University of Southern California School of
Medicine, in Los Angeles, each to be dual Professors of Neurology and Pathology, where, at
the USC-afﬁliated Good Samaritan Hospital, they established the USC Neuromuscular
Center. There, as Director of Research, Dr. Askanas set up her tissue-culture, electron-
microscopy, immunology, and biochemistry labs for continuing her work in investigating
pathogeneses of human neuromuscular diseases. She also developed a new model by
innervating aneurally-cultured human muscle ﬁbers by co-cultured fetal rat spinal-cord
motor neurons — that model produced neurogenically-twitching muscle ﬁbers
(reversibly-blockable by curare).
From about 1990 she has had a strong interest in the muscle abnormalities of patients
having sporadic inclusion-body myositis (sIBM) and hereditary inclusion-body myopa-
thies (hIBM). In her studies of sIBMmuscle, she and her teamhavediscovered exciting ab-
normalities related to the molecular pathogenesis of this still-untreatable disease,
including ﬁnding similarities to the neurodegenerative processes occurring in Alzheimer
and Parkinson disease brains, such as: accumulations within affected muscle ﬁbers of
amyloid-beta, tau, alpha-synuclein and parkin; defective proteasome and lysosomal
functions, and impaired mitochondrial functions. Her total bibliography includes more
than 400 publications. Her research has been funded by the NIH, including the NIA
prestigious Merit Award, MDA, Myositis Assn. and Alzheimer Assn.
Along with her laboratory research, Dr. Askanas clinically was managing neuromuscular
patients at the Los Angeles County Medical Center, until 2007, when she began devoting
all her neuromuscular efforts to her sIBM research. During her scientiﬁc careerDr. Askanas
trained a large number of Postdoctoral Fellows from various parts of the world, several of
who are now holding prestigious positions in their respective universities.
itorialWilliamKing Engel, MD earned his BA at Johns Hopkins and
his MD at McGill, including two summers at the Montreal
Neurological Institute. Next, at the University of Michigan
he had a neurology-major internship with Dr. R. DeJong.
Then training and an early career at the NIH, being trained
ﬁrst as a Clinical Associate fellow with Milton Shy (having
an emphasis on neuromuscular diseases), a year interlude
(clinical and neuropathology) at Queen Square, London,
and then back as NIH Medical Neurology Branch Chief,
NINDS (1952).
In 1962 he published the “The essentiality of histo- and
cytochemical studies of skeletal muscle in the investigation
of neuromuscular disease”, which earned the S.WeirMitchel
562 EdAward of the American Academy of Neurology, and was
reproduced as a landmark paper from the ﬁrst 50 years of the journal “Neurology”.
From thenon his research career has continued to be focused on applying the best possible
research techniques to the actual patients suffering with various then-untreatable
neuromuscular diseases, or specimens thereof (e.g.muscle biopsy, blood, and spinalﬂuid).
Over the years, this has led to many descriptions of new clinico-pathologic ﬁndings, new
diseases, and new successful treatments of previous untreatable conditions — and
to N700 publications describing them. Correspondingly, many patients have been very
gratifyingly treated. Quite important in those accomplishments have been the participation
of Dr. Engel's clinical and research excellent fellows, which have numbered over 230, many
of whom are themselves recognized experts on various aspects of neuromuscular diseases.
In 1981, Dr. Engel and Dr. Valerie Askanas were invited to the University of Southern
California School of Medicine, in Los Angeles, each as dual Professors of Neurology and
of Pathology, where, at the USC-afﬁliated Good Samaritan Hospital, they established the
USC Neuromuscular Center and continued their widely-recognized basic and clinical
neuromuscular research, including publishing and lecturing in numerous academic centers,
and at various international meetings and congresses. Dr. Engel has received numerous
awards and honors in this country and abroad.Valerie Askanas, Co-Editor*
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